Lexaria Bioscience Corp. (LEXX) has released an update.
Lexaria Bioscience Corp. has announced an 8-week animal study to investigate the efficacy of their DehydraTECH-processed drugs on diabetes and weight loss, focusing on blood glucose control and potential brain absorption enhancement. The study will test various formulations of GLP-1 and CBD, both separately and in combination, with over 1,500 blood plasma samples to be analyzed from 72 rats. The research aims to determine if the company’s proprietary processing technology increases brain absorption of the drugs, a hypothesis supported by previous studies.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
